NCT00509158View on ClinicalTrials.gov

Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Healthy
Interventions
BIOLOGICAL

arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant

BIOLOGICAL

arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

Sponsors

Collaborators (1)

Institut Pasteur
All Listed Sponsors
collaborator

Institut Pasteur

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT00509158 - Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine | Biotech Hunter | Biotech Hunter